PRAGUE, May 12, 2026 /PRNewswire/ -- Altesa BioSciences presented new research at the 2026 International Conference on Antiviral Research (ICAR) demonstrating that vapendavir, a rhinovirus capsid ...

-Proceeds to advance vapendavir, a first-in-class therapeutic for the treatment of rhinovirus, the predominant cause of respiratory exacerbations in millions with COPD and other chronic lung diseases- ...

Study objective is to demonstrate that treatment with vapendavir can mitigate or prevent worsening of respiratory symptoms caused by rhinovirus, which often lead to increased need for medical ...

COLLEGE PARK, Ga., May 7, 2025 /PRNewswire/ -- Altesa BioSciences today announced positive topline results from its Phase 2 placebo-controlled study examining the effects of vapendavir in COPD ...

Sanofi has backed the $75 million series B of a rhinovirus-focused biotech with a former FDA acting commissioner at the helm. Altesa BioSciences unveiled back in 2022 with $4 million in seed funding ...

Altesa BioSciences, a clinical-stage pharmaceutical company dedicated to preventing and treating the leading cause of COPD and asthma exacerbations, today announced it will be presenting its abstract ...

Altesa BioSciences has closed an oversubscribed $75m Series B funding round to advance the clinical development of its antiviral, vapendavir. With funding from lead investor Forbion, as well as ...

ATLANTA--(BUSINESS WIRE)--Altesa BioSciences, Inc. (Altesa), a clinical-stage biopharmaceutical company developing and commercializing novel antiviral drugs against common respiratory viruses and ...

ATLANTA--(BUSINESS WIRE)--Altesa BioSciences, Inc., a clinical-stage biopharmaceutical company developing and commercializing novel antiviral drugs against common respiratory viruses and global viral ...

Treatment improved patient reported outcomes, reduced viral load, and maintained lung function compared to placebo; Multi-center, international trial slated for 2026 AMSTERDAM, Sept. 28, 2025 ...

Antiviral improved overall patient-reported measures of both upper, lower respiratory symptoms, shortened overall course of illness COLLEGE PARK, Ga., May 7, 2025 /PRNewswire/ -- Altesa BioSciences ...

Altesa BioSciences begins enrolment in phase 2b CARDINAL trial of vapendavir as transformational treatment for patients with COPD impacted by rhinovirus: Atlanta ...